Feedback Share Discussion Threads

[yump] 27/11/2023 11:19

Why are you still here ?

[ydderf] 27/11/2023 10:57

Sentiment has changed for 'businesses' with no earnings and barely any sales. The fundamentals are assets which is IP and some burning net cash. A rational valuation would be projected net cash in say six months time and something for potential income which is realistically discounted to npv. According to my thinking that's about 30-35p. Happy to debate it rationally with someone seriously interested in agreeing what a fair arms length valuation might be. Anyone?

[yump] 24/11/2023 13:57

Palantir is not a day to day practical patient management tool. Bleepa is.

[digger2779] 23/11/2023 15:10

Looking at the 5 year chart we are pretty close to touching cloth so to speak. Can't quite make out the early 2020 bottom but it's not a pretty sight.

[gnnmartin] 23/11/2023 15:06

I did think the that the Palantir contract might be bad news for Feedback. If a hospital is 'given' the Palantir records handler, they will be less likely to get the funds to licence Bleeper: it will be argued that Bleeper is unnecessary given the Palantir product.

Anyone remember the Lorenzo fiasco? A health records system for the NHS being developed by Fujitsu, finally cancelled with losses of more than £10 billion in 2011.
hxxps://www.panorama-consulting.com/nhs-it-system-failure/#:~:text=Yet%2C%20nine%20years%20later%2C%20the,more%20than%20%C2%A310%20billion.

I suspect, as with the Post Office Horizon system, and hospital trying to say that the Palantir package is not fit for purpose will be ignored.

[ducatiman] 23/11/2023 14:33

Is that now an all time low?
Nice one TO. Still getting a big bonus? Still earning more than Rishi? Still can’t afford any shares?
Consolidation working out well?
Go now please and take a few other parasites with you

[yump] 22/11/2023 15:42

Our local surgery relocated to a nice newish overly large building, where the waiting room is generally 80% empty, because of phone “consultations”.

When you phone them the voice says “all our agents are busy”. “Agents” WTF ?

So amongst all the amazing tech developments and personalisations, the practice bought or subscribed to a sad generic phone system.

How bad a reflection on the attitude to us as customers is that and pretty dire reflection of either basic competence or the limitations of forced? choices available.

I have no confidence in the purchasing competence of any part of the NHS and I reckon it will be random luck if Bleepa gets chosen at QVH.

[lr2] 21/11/2023 18:26

It almost certainly won't work sufficiently well to achieve many of the stated aims. The government will declare it a success and the medical staff will work around large swathes of it. Money down a drain. Bleepa will be unlikely to be bothered by it.

[ged5] 21/11/2023 18:09

Further to that article, LR2, the NY Times article included this interesting sentence:-

On Tuesday, the N.H.S. said additional funds were set aside to build privacy features and for other companies to bid for building new products onto the platform in the future.

[lr2] 20/11/2023 23:30

Re my post #11077, it appears that despite the misgivings of many doctors Palantir has been given £480 million of taxpayers' money to implement their Federated Data Platform (FDP).



Our government is truly a soft touch.

[privateryan] 20/11/2023 17:00

And nobody wanted to buy it Internal budgets are for the birds. Rightly Tom shelved it

[ydderf] 20/11/2023 10:56

Texrad was the future, a future Feedback shareholders will never know now. The strategic decision to focus upon Bleepa has cost millions which could have been spent developing and marketing Texrad. To be fair, shareholders implicitly supported this move, which has turned out to be disastrous so far. Texrad had sales and internal projections in 2016-7 were for sales to be in the millions a few years down the line, i.e. a year or two ago.......

[ducatiman] 18/11/2023 15:51

Texrad is a superb product. The reason I first invested here.
A shame it is no longer being marketed and developed.
I’m sure one day it will be resurrected by someone.
It must have a value. If Fdbk don’t want it then sell it on.
I think I know someone who would like it!

[lr2] 17/11/2023 23:33

Another appearance of Texrad, this time in a thesis submitted to the University of Manchester for the degree of Doctor of Philosophy in the Faculty of Biology, Medicine and Health.

Investigating the potential of real-world data to improve outcomes for patients with lung cancer.

[ged5] 16/11/2023 11:33

You don't think there could possibly be some who have a longer time frame than the three weeks up to the QVH deadline? Surely not!

[lr2] 16/11/2023 11:27

And I thought we had a little leak last night. Wrong about that. Roll on the new financial year.

[ged5] 16/11/2023 10:52

I guess the answer is no. No trades so far today. Past the half way mark of November and still no news. Perhaps I should add on three months as I do for mining company deadlines.

[lr2] 15/11/2023 18:03

Some late interest today. Any chance of an RNS in the morning?

[lr2] 14/11/2023 12:00

Looks like he had second thoughts on the burger.

[lr2] 14/11/2023 11:49

Noticed the seller. Guess he needed a Big Mac whatever the price.

[ged5] 14/11/2023 11:37

Keeping your eye on things, LR2. Not sure it's going to bring in much revenue but good to know it's still being used. Thanks for 11091.

Noticed the big seller this morning. ;)

I can see why, Yump!

[lr2] 14/11/2023 11:07

Never hear anything about Texrad these days but it's still being used in test cases.

Scar characterisation to predict arrhythmia and death in ischaemic cardiomyopathy: insights from the REVIVED trial